文献速递胸部肿瘤放疗放疗物理与技术

PET调整的剂量涂绘IMRT治疗局部晚期非小细胞肺癌

Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-10-28

主要终点为IMRT后12至16周PET上治疗病灶无高残留代谢活性(SUVmax>6),30例可评估患者中24例(80%)达到;中位随访23.8个月,5例(14%)出现照射病灶进展,2年总生存率52%。

要点

  • 代谢体积>25 cm3的肿瘤或淋巴结接受65 Gy,较小病灶接受57 Gy或52.5 Gy。
  • 30例治疗后PET可评估患者中24例(80%)无高残留代谢活性,达到疗效目标。
  • 高危病灶与低危病灶2年局部进展累积发生率分别为9%与3%。

核心结论

  • 基于治疗前PET指标的剂量涂绘IMRT联合同步化疗,在局部晚期NSCLC中取得较高的代谢缓解率和局部疾病控制率。

主要发现

  • 30例接受治疗后PET的患者中24例(80%)达到主要终点,即治疗病灶无SUVmax>6的高残留代谢活性。
  • 中位随访23.8个月(存活患者),5例(14%)出现照射病灶进展。
  • 高危病灶(n=24)与低危病灶(n=92)的2年局部进展累积发生率分别为9%和3%。
  • 2年总生存率为52%。

关键数值与推荐

  • 代谢肿瘤体积>25 cm3的肿瘤或淋巴结判为「高危」,接受65 Gy。
  • 较小病灶接受57 Gy,2014年11月后为52.5 Gy。
  • 主要终点为IMRT完成后12至16周PET上治疗病灶无最高标准化摄取值>6的高残留代谢活性。

临床怎么用

  • 可依据治疗前PET代谢体积对局部晚期NSCLC进行剂量分层涂绘IMRT,高危病灶给65 Gy,并同步每周卡铂与紫杉醇化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform a prospective trial examining positron emission tomography (PET)-based, dose-painted intensity modulated radiation therapy (IMRT) in the setting of locally advanced non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Patients with stage IIB-III NSCLC were treated with 25 fractions of dose-painted IMRT. Tumors or lymph nodes with metabolic tumor volume exceeding 25 cm3 were deemed "high risk" and received 65 Gy. Smaller lesions were treated with 57 Gy or 52.5 Gy (after November 2014). Patients received concurrent weekly carboplatin (area under the curve = 2) and paclitaxel (45 mg/m2). The primary study endpoint was the absence of high residual metabolic activity (maximum standardized uptake value > 6) in treated lesions on PET 12 to 16 weeks after completion of IMRT. RESULTS: Thirty-five subjects with 116 hypermetabolic lesions were eligible for analysis. The primary endpoint was met for 24 of 30 patients (80%) who underwent posttreatment PET, satisfying our efficacy objective. With a median follow-up duration of 23.8 months for living patients, progression in a lesion targeted with radiation therapy has been observed in 5 patients (14%). Treating progression in other sites and death without progression as competing risks, 2-year cumulative incidence rates of local disease progression in high-risk lesions (n=24) and low-risk lesions (n=92) are 9% and 3%, respectively. The actuarial rate of overall survival at 2 years is 52%. CONCLUSIONS: Dose-painted IMRT based on pretreatment PET metrics with concurrent chemotherapy yields high rates of metabolic response and local disease control for locally advanced NSCLC. Future trials should test this approach to maximize the therapeutic ratio of thoracic radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ohri N, Bodner WR, Kabarriti R, et al. Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29249527. doi:10.1016/j.ijrobp.2017.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。